AU Stock MarketDetailed Quotes
ALA Arovella Therapeutics Ltd
- 0.205
- 0.0000.00%
20min DelayMarket Closed Nov 15 15:59 AET
216.80MMarket Cap-22777P/E (Static)
0.205High0.202Low897.95KVolume0.205Open0.205Pre Close183.71KTurnover0.21052wk High0.12%Turnover Ratio1.06BShares0.08052wk Low-0.009EPS TTM155.80MFloat Cap360.698Historical HighLossP/E (Static)760.00MShs Float0.020Historical Low-0.009EPS LYR1.46%Amplitude--Dividend TTM18.64P/B1Lot Size--Div YieldTTM
About Arovella Therapeutics Ltd Company
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.
Company Profile
SymbolALA
Company NameArovella Therapeutics Ltd
Founded1999
MarketASX
Employees14
Fiscal Year Ends06-30
Address84 Hotham Street Corporate One
CityPreston
CountryAustralia
Zip Code3072
Phone+61 398636472
Websitehttps://www.arovella.com
Share RegistryAUTOMIC REGISTRY SERVICES
477 Collins Street, MELBOURNE, VIC, AUSTRALIA, 3000
1300 288 664
Company Executives
- Name
- Position
- Salary
- Michael Baker
- Chief Executive Officer,Managing Director
- --
- Thomas (Tom) Duthy
- Non-Executive Chairman,Non-Executive Director
- --
- Gary Phillips
- Non-Executive Director
- --
- Elizabeth Stoner
- Non-Executive Director
- --
- Debora Barton
- Non-Executive Director
- --
Analysis
Price Target
No Data
Heat List
AU
Overall
Symbol
Latest Price
% Chg
No Data